Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. Trials Nordlund, J., Henry, R. S., Kwakkenbos, L., Carrier, M., Levis, B., Nielson, W. R., Bartlett, S. J., Dyas, L., Tao, L., Fedoruk, C., Nielsen, K., Hudson, M., Pope, J., Frech, T., Gholizadeh, S., Johnson, S. R., Piotrowski, P., Jewett, L. R., Gordon, J., Chung, L., Bilsker, D., Levis, A. W., Turner, K. A., Cumin, J., Welling, J., Fortune, C., Leite, C., Gottesman, K., Sauve, M., Rodriguez-Reyna, T. S., Larche, M., van Breda, W., Suarez-Almazor, M. E., Wurz, A., Culos-Reed, N., Malcarne, V. L., Mayes, M. D., Boutron, I., Mouthon, L., Benedetti, A., Thombs, B. D., SPIN Investigators, Riggs, R., Assassi, S., El-Baalbaki, G., Ells, C., van den Ende, C., Fligelstone, K., Gietzen, A., Guillot, G., Harel, D., Hinchcliff, M., Nguyen, C., Rannou, F., Richard, M., Schouffoer, A. A., Agard, C., Abdallah, N. A., Albert, A., Andre, M., Bernstein, E. J., Berthier, S., Bissonnette, L., Bruns, A., Carreira, P., Casadevall, M., Chaigne, B., Correia, C., Crichi, B., Denton, C., Domsic, R., Dunne, J. V., Dunogue, B., Fare, R., Farge-Bancel, D., Fortin, P. R., Granel-Rey, B., Gyger, G., Hachulla, E., Herrick, A. L., Hoa, S., Ikic, A., Jones, N., Kafaja, S., Khalidi, N., Lambert, M., Launay, D., Maillard, H., Maltez, N., Manning, J., Marie, I., Martin, M., Martin, T., Masetto, A., Maurier, F., Mekinian, A., Melchor, S., Nikpour, M., Olagne, L., Poindron, V., Proudman, S., Regent, A., Riviere, S., Robinson, D., Rodriguez, E., Roux, S., Smets, P., Sobanski, V., Spiera, R., Steen, V., Sutton, E., Thorne, C., Varga, J., Wilcox, P., Bourgeault, A., Ayala, M. C., Jimenez, A. C., Discepola, M., Gagarine, M., Ostbo, N. 2021; 22 (1): 856

Abstract

BACKGROUND: Systemic sclerosis (scleroderma; SSc) is a rare autoimmune connective tissue disease. We completed an initial feasibility trial of an online self-administered version of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program using the cohort multiple randomized controlled trial (RCT) design. Due to low intervention offer uptake, we will conduct a new feasibility trial with progression to full-scale trial, using a two-arm parallel, partially nested RCT design. The SPIN-SELF Program has also been revised to include facilitator-led videoconference group sessions in addition to online material. We will test the group-based intervention delivery format, then evaluate the effect of the SPIN-SELF Program on disease management self-efficacy (primary) and patient activation, social appearance anxiety, and functional health outcomes (secondary).METHODS: This study is a feasibility trial with progression to full-scale RCT, pending meeting pre-defined criteria, of the SPIN-SELF Program. Participants will be recruited from the ongoing SPIN Cohort ( http://www.spinsclero.com/en/cohort ) and via social media and partner patient organizations. Eligible participants must have SSc and low to moderate disease management self-efficacy (Self-Efficacy for Managing Chronic Disease (SEMCD) Scale score = 7.0). Participants will be randomized (1:1 allocation) to the group-based SPIN-SELF Program or usual care for 3 months. The primary outcome in the full-scale trial will be disease management self-efficacy based on SEMCD Scale scores at 3 months post-randomization. Secondary outcomes include SEMCD scores 6 months post-randomization plus patient activation, social appearance anxiety, and functional health outcomes at 3 and 6 months post-randomization. We will include 40 participants to assess feasibility. At the end of the feasibility portion, stoppage criteria will be used to determine if the trial procedures or SPIN-SELF Program need important modifications, thereby requiring a re-set for the full-scale trial. Otherwise, the full-scale RCT will proceed, and outcome data from the feasibility portion will be utilized in the full-scale trial. In the full-scale RCT, 524 participants will be recruited.DISCUSSION: The SPIN-SELF Program may improve disease management self-efficacy, patient activation, social appearance anxiety, and functional health outcomes in people with SSc. SPIN works with partner patient organizations around the world to disseminate its programs free-of-charge.TRIAL REGISTRATION: ClinicalTrials.gov NCT04246528 . Registered on 27 January 2020.

View details for DOI 10.1186/s13063-021-05827-z

View details for PubMedID 34838105